Login to Your Account

Vaccines Firm Goes to Vivalis in All-Share Deal Worth $175M

By Nuala Moran
Staff Writer

Wednesday, December 19, 2012
The French vaccines manufacturing technology company Vivalis SA is acquiring Austrian vaccines discoverer and developer Intercell AG, of Vienna, in an all-share deal valued at €133 million (US$175 million).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription